Remix Therapeutics has appointed Christopher Bowden, MD, as chief medical officer.
Remix Therapeutics is a biotechnology company focusing on modulating RNA processing through small molecule therapies to address the underlying causes of disease, according to a Jan. 5 release from the company.
Dr. Bowden previously served as the chief medical officer and a strategy adviser for Agios from 2014 to 2022. He also spent eight years at Genentech, where he was the vice president of product development oncology.
Dr. Bowden also has experience as the executive director of the Europe, Middle East and Africa regions for New York-based pharmaceutical company Bristol-Myers Squibb.